Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells J.; Glassman A.; Ayala Allison R.; Jampol L.; Aiello L. P.; Antoszyk A.; Arnold-Bush Bambi; Baker C.; Bressler N.; Browning David J.; Elman M.; Ferris Frederick L.; Friedman Scott M.; Melia M.; Pieramici D.; Sun Jennifer K.; Beck R. W.

doi:10.1056/nejmoa1414264

← Today's brief

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Wells J. et al. · The New England journal of medicine · Thursday, January 1, 2015

Funding Not reported

Source

Wells J. et al.. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. The New England journal of medicine. Thursday, January 1, 2015.
doi:10.1056/nejmoa1414264Read original ↗

Generated, then checked against the source · how this brief was built →

Sign in to rate and bookmark articles

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.